M. Kulyk & Associates, LLC Regeneron Pharmaceuticals, Inc. Transaction History
M. Kulyk & Associates, LLC
- $422 Million
- Q1 2025
A detailed history of M. Kulyk & Associates, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, M. Kulyk & Associates, LLC holds 2,687 shares of REGN stock, worth $1.62 Million. This represents 0.4% of its overall portfolio holdings.
Number of Shares
2,687
Previous 2,159
24.46%
Holding current value
$1.62 Million
Previous $1.54 Million
10.87%
% of portfolio
0.4%
Previous 0.34%
Shares
2 transactions
Others Institutions Holding REGN
# of Institutions
1,469Shares Held
85.8MCall Options Held
1.39MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA9.41MShares$5.69 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.11 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.42 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.9 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$2.41 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $64.8B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...